comparemela.com

Latest Breaking News On - Child level menu hover - Page 1 : comparemela.com

China's NMPA accepts Legend Biotech's NDA for cilta-cel - Pharmaceutical Business review

Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects

Menu-hover
Subchild-level-menu-hover
Child-level-menu-hover
End-third-level
Bend-article
End-timeline

Vistagen agrees to acquire Pherin Pharmaceuticals

Vistagen has signed a definitive agreement for the acquisition of clinical-stage drug development firm Pherin Pharmaceuticals.

Shawn-singh
Pherin-pharmaceuticals
Robina-weermeijer
Menu-hover
Subchild-level-menu-hover
Child-level-menu-hover
End-third-level
Bend-article
End-timeline

FDA grants fast track designation for Kintara's breast cancer therapy

The US FDA has granted fast track designation (FTD) for Kintara Therapeutics’ REM-001, to treat cutaneous metastatic breast cancer (CMBC).

Menu-hover
Subchild-level-menu-hover
Child-level-menu-hover
End-third-level
Bend-article
End-timeline

Everest regulatory updates in Taiwan, South Korea for Nefecon

The regulatory authorities in Taiwan and South Korea have granted fast-tracked approval process for Everest Medicines’ Nefecon.

Menu-hover
Subchild-level-menu-hover
Child-level-menu-hover
End-third-level
Bend-article
End-timeline

ViiV Healthcare, Medicines Patent Pool partner to expand HIV drug access

ViiV Healthcare and the Medicines Patent Pool (MPP) have entered into a voluntary licensing agreement to expand access to cabotegravir

Charles-gore
Deborah-waterhouse
Sustainable-development-goal
National-cancer-institute-on-unsplash
Drug-administration
Medicines-patent-pool
National-cancer-institute
Sub-saharan-african
Menu-hover
Subchild-level-menu-hover
Child-level-menu-hover

vimarsana © 2020. All Rights Reserved.